Staccato Zaleplon Single Dose Pharmacokinetics

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine the safety, tolerability and pharmacokinetics of zaleplon delivered by the Staccato thermal aerosol system in healthy volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alexza Pharmaceuticals, Inc.
• Treatments: Zaleplon

Criteria

Inclusion Criteria:

• Male and female subjects between the ages of 18 to 55 years, inclusive who are in good general health

Exclusion Criteria:

• Subjects with a history of allergy or intolerance to zaleplon. Subjects who have any other disease or condition, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.